Research programme: small molecule therapeutics - Chipscreen Biosciences

Drug Profile

Research programme: small molecule therapeutics - Chipscreen Biosciences

Alternative Names: CS 3158; CS 410; CS 510; CS00028; CS0220; CS0230; CS0240; CS0600; HDAC inhibitors - Chipscreen; Histone deacetylase inhibitors - Chipscreen Biosciences; Kinase inhibitors - Chipscreen Bioscience; VEGFR inhibitors - Chipscreen Biosciences

Latest Information Update: 28 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chipscreen Biosciences
  • Class Small molecules
  • Mechanism of Action HDAC1 protein inhibitors; HDAC2 protein inhibitors; Histone deacetylase inhibitors; Janus kinase 3 inhibitors; MAP kinase kinase kinase 5 inhibitors; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Autoimmune disorders; Cardiovascular disorders; Neurodegenerative disorders; Rheumatoid arthritis; Solid tumours
  • Discontinued Viral infections

Most Recent Events

  • 28 May 2018 No recent reports of development identified for preclinical development in Cardiovascular-disorders in China
  • 28 May 2018 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in China
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Autoimmune-disorders in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top